| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |